{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T02:17:47Z","timestamp":1785377867296,"version":"3.55.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>People living with HIV (PWH) have an increased risk of developing aggressive skin cancers, yet they have been largely excluded from immune checkpoint inhibitor (ICI) trials. Consequently, evidence on the safety and efficacy of ICIs in this population remains scarce, particularly for the nivolumab plus ipilimumab (NIVO+IPI) combination.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicentre, real-world study included PWH treated with ICIs for melanoma or non-melanoma skin cancers. The objective was to evaluate patient characteristics, treatment management, and clinical outcomes across the different skin cancer types.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 54 patients, 89% were male, and 92.6% had a suppressed HIV viral load. Melanoma was the most frequent tumour (35\/54, 64.8%), followed by cutaneous squamous cell carcinoma (12\/54, 22.2%), Kaposi sarcoma (4\/54, 7.4%), basal cell carcinoma (2\/54, 3.7%), and one Merkel cell carcinoma. Anti-PD-1\/PD-L1 monotherapy was given as first-line treatment in 81.5% (44\/54). Immune-related adverse events (irAEs) occurred in 42.6% (23\/54), with a median onset of 43.5\u2009days (IQR, 20.5\u2013126). The maximum toxicity grade was 1\/2 in 39% (21\/54), grade \u2265 3 in 13% (7\/54). Seventeen melanoma patients received NIVO+IPI. Among them, 64.7% (11\/17) experienced irAEs, including grade \u2265 3 events in 30% (5\/17). Objective response rates were 43% (9\/21) in melanoma, 58% (7\/12) in cSCC, and 75% (3\/4) in Kaposi sarcoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PWH treated with ICIs for skin cancer demonstrated favourable outcomes, with a notably reassuring safety profile of NIVO+IPI. These findings support managing well-controlled PWH similarly to the general population and highlight the importance of including this population across all settings of skin cancer trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf419","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T12:36:41Z","timestamp":1765802201000},"source":"Crossref","is-referenced-by-count":1,"title":["Real-world outcomes of immune checkpoint inhibitors in people with HIV and skin cancer: a multicentre study"],"prefix":"10.1093","volume":"31","author":[{"given":"Andr\u00e9a Cl\u00e9ment","family":"de Givry","sequence":"first","affiliation":[{"name":"Departement of Dermatology, H\u00f4pital Bichat-Claude-Bernard AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Manchon","sequence":"additional","affiliation":[{"name":"Clinical Investigation Centre, H\u00f4pital Bichat-Claude-Bernard AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Veyri","sequence":"additional","affiliation":[{"name":"H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re, AP-HP Departement of Medical Oncology, Institut Pierre Louis d'\u00c9pid\u00e9miologie et de Sant\u00e9 Publique (iPLESP), INSERM, Sorbonne Universit\u00e9, , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Delyon","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, H\u00f4pital Saint-Louis AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7211-9658","authenticated-orcid":false,"given":"Nausicaa","family":"Malissen","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, H\u00f4pital La Timone AP-HM , Marseille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Gaudy-Marqueste","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, H\u00f4pital La Timone AP-HM , Marseille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ouidad","family":"Zehou","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, H\u00f4pital Henri Mondor AP-HP , Cr\u00e9teil,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jannic","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, Centre Hospitalier Intercommunal de Cr\u00e9teil , Cr\u00e9teil,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie","family":"G\u00e9rard","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, H\u00f4pital Pellegrin , Bordeaux,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Kramkimel","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, H\u00f4pital Cochin AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Longvert","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, H\u00f4pital Ambroise Par\u00e9 AP-HP , Boulogne-Billancourt,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eve","family":"Maubec","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, H\u00f4pital Avicenne AP-HP , Bobigny,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0924-7371","authenticated-orcid":false,"given":"Marie","family":"Boileau","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, Centre Hospitalier Universitaire de Lille , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Emmanuel","family":"Stoebner","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, Centre Hospitalier Universitaire de N\u00eemes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri","family":"Montaudi\u00e9","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, Centre Hospitalier Universitaire de Nice , Nice,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Qu\u00e9reux","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, Centre Hospitalier Universitaire de Nantes , Nantes,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Matthieu","family":"L\u2019Orphelin","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, Centre Hospitalier Universitaire de Caen , Caen,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Poirier","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, H\u00f4pital Saint-Joseph , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Girard","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, Centre Hospitalier Universitaire de Montpellier , Montpellier,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9902-5990","authenticated-orcid":false,"given":"Charl\u00e9e","family":"Nardin","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, Centre Hospitalier Universitaire de Besan\u00e7on , Besan\u00e7on,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Mortier","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, Centre Hospitalier Universitaire de Lille , Lille,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentine-Marie","family":"Ferr\u00e9","sequence":"additional","affiliation":[{"name":"Departement of Virology, H\u00f4pital Bichat-Claude-Bernard AP-HP, INSERM IAME Universit\u00e9 Paris Cit\u00e9, INSERM UMR 1137 IAME , , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Descamps","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, H\u00f4pital Bichat-Claude-Bernard AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Spano","sequence":"additional","affiliation":[{"name":"Departement of Medical Oncology, H\u00f4pital Piti\u00e9-Salp\u00e9tri\u00e8re AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Laouenan","sequence":"additional","affiliation":[{"name":"INSERM Universit\u00e9 Paris Cit\u00e9 , IAME UMR 1137 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2914-959X","authenticated-orcid":false,"given":"Jade","family":"Ghosn","sequence":"additional","affiliation":[{"name":"Departement of Infectious Diseases, H\u00f4pital Bichat-Claude-Bernard AP-HP Universit\u00e9 Paris Cit\u00e9, INSERM UMR 1137 IAME , , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9leste","family":"Lebb\u00e9","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, H\u00f4pital Saint-Louis AP-HP , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2100-2913","authenticated-orcid":false,"given":"Florence","family":"Brunet Possenti","sequence":"additional","affiliation":[{"name":"Departement of Dermatology, H\u00f4pital Bichat-Claude-Bernard AP-HP, INSERM IAME, Universit\u00e9 Paris Cit\u00e9 , Paris,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,12,15]]},"reference":[{"key":"2026010713412742400_oyaf419-B1","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"2026010713412742400_oyaf419-B2","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1158\/1078-0432.CCR-21-2971","article-title":"Immunotherapy for nonmelanoma skin cancer: facts and hopes","volume":"28","author":"Shalhout","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2026010713412742400_oyaf419-B3","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.ccell.2023.07.011","article-title":"Neoadjuvant immune checkpoint blockade: a window of opportunity to advance cancer immunotherapy","volume":"41","author":"Topalian","year":"2023","journal-title":"Cancer Cell"},{"key":"2026010713412742400_oyaf419-B4","doi-asserted-by":"crossref","first-page":"TPS9605","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9605","article-title":"The NADINA trial: a multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma","volume":"40","author":"Lucas","year":"2022","journal-title":"JCO"},{"key":"2026010713412742400_oyaf419-B5","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"2026010713412742400_oyaf419-B6","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa2209813","article-title":"Neoadjuvant cemiplimab for stage II to IV cutaneous Squamous-Cell carcinoma","volume":"387","author":"Gross","year":"2022","journal-title":"N. Engl. J. Med"},{"key":"2026010713412742400_oyaf419-B7","doi-asserted-by":"crossref","first-page":"e180077","DOI":"10.1001\/jamaoncol.2018.0077","article-title":"Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic merkel cell carcinoma: a preplanned interim analysis of a clinical trial","volume":"4","author":"D\u2019Angelo","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026010713412742400_oyaf419-B8","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S1470-2045(22)00097-3","article-title":"PD-1 blockade with pembrolizumab in classic or endemic kaposi\u2019s sarcoma: a multicentre, single-arm, phase 2 study","volume":"23","author":"Delyon","year":"2022","journal-title":"Lancet Oncol"},{"key":"2026010713412742400_oyaf419-B9","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.annonc.2023.10.123","article-title":"Final analysis of phase II results with cemiplimab in metastatic basal cell carcinoma after hedgehog pathway inhibitors","volume":"35","author":"Lewis","year":"2024","journal-title":"Ann. Oncol"},{"key":"2026010713412742400_oyaf419-B10","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jaad.2018.03.024","article-title":"Risk of skin cancer in patients with HIV: a danish nationwide cohort study","volume":"79","author":"Omland","year":"2018","journal-title":"J. Am. Acad. Dermatol"},{"key":"2026010713412742400_oyaf419-B11","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1200\/JCO.2014.59.5967","article-title":"Elevated cancer-specific mortality among HIV-infected patients in the United States","volume":"33","author":"Coghill","year":"2015","journal-title":"J. Clin. Oncol"},{"key":"2026010713412742400_oyaf419-B12","doi-asserted-by":"crossref","first-page":"e251589","DOI":"10.1001\/jamaoncol.2025.1589","article-title":"Cancer incidence and trends in US adults with HIV","volume":"11","author":"Haas","year":"2025","journal-title":"JAMA Oncol"},{"key":"2026010713412742400_oyaf419-B13","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.jid.2022.09.008","article-title":"Risk of nonkeratinocyte skin cancers in people living with HIV during the era of antiretroviral therapy","volume":"143","author":"Luu","year":"2023","journal-title":"J. Invest. Dermatol"},{"key":"2026010713412742400_oyaf419-B14","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.3390\/cancers13225702","article-title":"Kaposi\u2019s sarcoma in virally suppressed people living with HIV: an emerging condition","volume":"13","author":"Palich","year":"2021","journal-title":"Cancers"},{"key":"2026010713412742400_oyaf419-B15","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1016\/S2352-3018(23)00202-3","article-title":"Skin cancer risk in people living with HIV: a call for action","volume":"11","author":"Reinhart","year":"2024","journal-title":"Lancet HIV"},{"key":"2026010713412742400_oyaf419-B16","doi-asserted-by":"crossref","first-page":"6637","DOI":"10.1038\/s41598-021-86081-w","article-title":"Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials","volume":"11","author":"Vora","year":"2021","journal-title":"Sci. Rep"},{"key":"2026010713412742400_oyaf419-B17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1634\/theoncologist.2019-0853","article-title":"Inclusive cancer care: rethinking patients living with HIV and cancer","volume":"25","author":"Corrigan","year":"2020","journal-title":"Oncologist"},{"key":"2026010713412742400_oyaf419-B18","doi-asserted-by":"crossref","first-page":"3712","DOI":"10.1200\/JCO.22.02459","article-title":"Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: a real-world report from the cancer therapy using checkpoint inhibitors in people living with HIV-international (CATCH-IT) consortium","volume":"41","author":"El Zarif","year":"2023","journal-title":"J. Clin. Oncol"},{"key":"2026010713412742400_oyaf419-B19","doi-asserted-by":"crossref","first-page":"e009728","DOI":"10.1136\/jitc-2024-009728","article-title":"Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study","volume":"12","author":"Assoumou","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"2026010713412742400_oyaf419-B20","doi-asserted-by":"crossref","first-page":"F13","DOI":"10.1097\/QAD.0000000000002298","article-title":"Immunotherapy for cancer in people living with HIV: safety with an efficacy signal from the series in real life experience","volume":"33","author":"Spano","year":"2019","journal-title":"AIDS"},{"key":"2026010713412742400_oyaf419-B21","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer\u2014A phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026010713412742400_oyaf419-B22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11904-020-00525-y","article-title":"Anti PD-1 and anti PD-L1 monoclonal antibodies in people living with HIV and cancer","volume":"17","author":"Lurain","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2026010713412742400_oyaf419-B23","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1200\/JCO.2017.73.7916","article-title":"Broadening eligibility criteria to make clinical trials more representative: American society of clinical oncology and friends of cancer research joint research statement","volume":"35","author":"Kim","year":"2017","journal-title":"J. Clin. Oncol"},{"key":"2026010713412742400_oyaf419-B24","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/07357907.2025.2462568","article-title":"Exclusion of people living with HIV in aggressive B-Cell Non-Hodgkin lymphoma studies: a cross-sectional analysis of clinical trials from 2014 to 2024","volume":"43","author":"Olivieri","year":"2025","journal-title":"Cancer Invest"},{"key":"2026010713412742400_oyaf419-B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.1517","article-title":"Inclusion of people living with HIV in food and drug administration (FDA) oncology pivotal registration trials from 2020 to 2024","author":"Lythgoe","year":"2025","journal-title":"J. Clin. Oncol"},{"key":"2026010713412742400_oyaf419-B26","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(02)07668-7","article-title":"Merkel cell carcinoma and HIV infection","volume":"359","author":"Engels","year":"2002","journal-title":"Lancet"},{"key":"2026010713412742400_oyaf419-B27","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1001\/jamadermatol.2024.4607","article-title":"Merkel cell carcinoma and immunosuppression, UV radiation, and merkel cell polyomavirus","volume":"161","author":"Tribble","year":"2025","journal-title":"JAMA Dermatol"},{"key":"2026010713412742400_oyaf419-B28","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1200\/JCO.24.00640","article-title":"Cancer immunotherapy trials network 12: pembrolizumab in HIV-associated kaposi sarcoma","volume":"43","author":"Lurain","year":"2025","journal-title":"J. Clin. Oncol"},{"key":"2026010713412742400_oyaf419-B29","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and Advanced-Stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026010713412742400_oyaf419-B30","doi-asserted-by":"crossref","first-page":"e006127","DOI":"10.1136\/jitc-2022-006127","article-title":"First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817","volume":"11","author":"Ready","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"2026010713412742400_oyaf419-B31","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2022.09.004","article-title":"Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study","volume":"176","author":"Serra-Bellver","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"2026010713412742400_oyaf419-B32","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature05115","article-title":"PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression","volume":"443","author":"Day","year":"2006","journal-title":"Nature"},{"key":"2026010713412742400_oyaf419-B33","doi-asserted-by":"crossref","first-page":"103840","DOI":"10.1016\/j.ebiom.2022.103840","article-title":"Immune checkpoint blockade in HIV","volume":"76","author":"Gubser","year":"2022","journal-title":"EBioMedicine"},{"key":"2026010713412742400_oyaf419-B34","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/s41392-024-01943-9","article-title":"Anti-PD-L1 antibody ASC22 in combination with a histone deacetylase inhibitor chidamide as a \u201cshock and kill\u201d strategy for ART-free virological control: a phase II single-arm study","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target Ther"},{"key":"2026010713412742400_oyaf419-B35","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.3390\/cells10092227","article-title":"Immune checkpoint inhibitors in people living with HIV\/AIDS: facts and controversies","volume":"10","author":"Castelli","year":"2021","journal-title":"Cells"},{"key":"2026010713412742400_oyaf419-B36","doi-asserted-by":"publisher","author":"Shah","year":"2022","DOI":"10.6004\/jnccn.2022.7020"},{"key":"2026010713412742400_oyaf419-B37","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/QAD.0000000000000993","article-title":"Steroids are a risk factor for kaposi\u2019s sarcoma-immune reconstitution inflammatory syndrome and mortality in HIV infection","volume":"30","author":"Fern\u00e1ndez-S\u00e1nchez","year":"2016","journal-title":"AIDS"},{"key":"2026010713412742400_oyaf419-B38","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1200\/JCO.22.02575","article-title":"Neoadjuvant checkpoint immunotherapy and melanoma: the time is now","volume":"41","author":"Long","year":"2023","journal-title":"J. Clin. Oncol"},{"key":"2026010713412742400_oyaf419-B39","doi-asserted-by":"crossref","first-page":"e011652","DOI":"10.1136\/jitc-2025-011652","article-title":"Therapeutic potential of targeting LAG-3 in cancer","volume":"13","author":"Davar","year":"2025","journal-title":"J Immunother Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf419\/65884388\/oyaf419.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/1\/oyaf419\/65884388\/oyaf419.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/1\/oyaf419\/65884388\/oyaf419.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T18:41:40Z","timestamp":1767811300000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf419\/8380179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,15]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,27]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf419","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,12,15]]},"article-number":"oyaf419"}}